Furthermore, administration of neutralizing antibodies against TL1A ameliorated both AIA and CIA [63], suggesting that the TL1A-DR3 pathway may be a potential therapeutic target in RA patients. The gene discussed is TNFSF15; the disease is rheumatoid arthritis.